The BTKi rollercoaster in MS continues to surprise

The BTKi rollercoaster in MS continues to surprise

Author: Nikita Shah, Beyond Neurology The rollercoaster in the MS fairground has taken another sharp turn. Tolebrutinib has missed its primary endpoint in the Phase 3 PERSEUS trial in PPMS, and the already delayed FDA decision for its nrSPMS indication now looks...
Spotlight on BTK Inhibitors in MS

Spotlight on BTK Inhibitors in MS

In recent years, interest in BTK inhibitors (BTKi) for MS has surged, with hopes that they could offer a new way to tackle the underlying drivers of the disease. But the journey, so far, has been a rollercoaster, and the delayed FDA decision on tolebrutinib marks the...